Iincyclinide, also known as CMT-3 and COL-3, is an MMP inhibitor and a chemically-modified tetracycline with potential antineoplastic activity patented by Chas. Pfizer & Co. Incyclinide has been shown to experimentally suppress prostate cancer, colon adenocarcinoma and melanoma invasiveness in cell culture. Incyclinide is an especially effective inhibitor of the growth and viability of filamentous fungi. Unfortunately, in clinical trials, Iincyclinide failed to demonstrate efficacy in Lymphoma, Melanoma, Renal Cell Carcinoma, and some other tumors.